Real-world effectiveness of nirsevimab over three RSV seasons in an integrated health care system: a target trial emulation study

Most nirsevimab effectiveness estimates come from test-negative designs, which restrict populations to those seeking healthcare and testing. We estimated nirsevimab effectiveness among infants six months post-receipt using a target trial emulation with an estimand aligned to phase 3 trials. We emulated a target trial among infants born from February 2, 2023 through May 30, 2026, using electronic medical records at Kaiser Permanente Georgia. Using a g-computation estimator with Cox models fit separately in nirsevimab recipients and non-recipients, we estimated the cumulative incidence of RSV hospitalization and medically-attended RSV at 30-day intervals through 180 days post-receipt. Among 4,826 infants, nirsevimab reduced the risk of RSV hospitalization by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) at 180 days post-receipt. The number needed to immunize to prevent one case was 147 (95% CI: 94 to 333) for RSV hospitalization and 39 (95% CI: 28 to 68) for medically-attended RSV. Nirsevimab was effective through 180 days post-receipt. This cohort-based emulation avoids conditioning on testing and the restricted generalizability of the test-negative and matching-based designs that dominate the literature. These findings support continued nirsevimab use to protect infants against RSV.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-15
DOI
https://doi.org/10.64898/2026.11.12.26367940
Primary Topic
Respiratory viral infections research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Real-world effectiveness of nirsevimab over three RSV seasons in an integrated health care system: a target trial emulation study

Marina Bruck, Felipe Lobelo, David C. Benkeser, Elizabeth T. Rogawski McQuade et al.
medRxiv
Respiratory viral infections research
preprint

Real-world effectiveness of nirsevimab over three RSV seasons in an integrated health care system: a target trial emulation study

Marina Bruck, Felipe Lobelo, David C. Benkeser, Elizabeth T. Rogawski McQuade, Mackenzie Crawford, Sara S. Kim, Alexander F. Hudgins, Emily Wu
preprint en

Abstract

Most nirsevimab effectiveness estimates come from test-negative designs, which restrict populations to those seeking healthcare and testing. We estimated nirsevimab effectiveness among infants six months post-receipt using a target trial emulation with an estimand aligned to phase 3 trials. We emulated a target trial among infants born from February 2, 2023 through May 30, 2026, using electronic medical records at Kaiser Permanente Georgia. Using a g-computation estimator with Cox models fit separately in nirsevimab recipients and non-recipients, we estimated the cumulative incidence of RSV hospitalization and medically-attended RSV at 30-day intervals through 180 days post-receipt. Among 4,826 infants, nirsevimab reduced the risk of RSV hospitalization by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) at 180 days post-receipt. The number needed to immunize to prevent one case was 147 (95% CI: 94 to 333) for RSV hospitalization and 39 (95% CI: 28 to 68) for medically-attended RSV. Nirsevimab was effective through 180 days post-receipt. This cohort-based emulation avoids conditioning on testing and the restricted generalizability of the test-negative and matching-based designs that dominate the literature. These findings support continued nirsevimab use to protect infants against RSV.

medRxiv
Kaiser Permanente (US), Emory University (US), Colorado Permanente Medical Group (US)
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Real-world effectiveness of nirsevimab over three RSV seasons in an integrated health care system: a target trial emulation study — Marina Bruck, Felipe Lobelo, et al. · medRxiv (2026) | TGRS Research Map | TGRS